跳至主要内容
临床试验/jRCT2031250033
jRCT2031250033招募中不适用

A Phase I study evaluating safety, tolerability, and immunogenicity of FPP004X intramuscularly administered (FPP004X-JP-SAR-01)

FunPep Co., Ltd.0 个研究点目标入组 93 人开始时间: 2025年4月17日最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
93
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized Controlled Trial
干预模型
Parallel Assignment
主要目的
Treatment Purpose
盲法
Double Blind

入排标准

年龄范围
18age old over 至 50age old not(—)
性别
Male

入选标准

  • Healthy adults(Part 1):
  • Males aged >= 18 to < 45 years at the time of consent
  • Body mass index (BMI) >= 18.5 kg/m2 to < 25.0 kg/m2
  • Patients with seasonal allergic rhinitis(Part 2):
  • Males aged >= 18 to < 50 years at the time of consent
  • Body mass index (BMI) >= 17.6 kg/m2 to < 26.5 kg/m2

排除标准

  • Subjects who who have participated (been vaccinated) in a clinical trial of an unapproved vaccine within 1 year prior to the start of the clinical trial (starting from the date of administration of the investigational drug)
  • Subjects who have been diagnosed with immunodeficiency or autoimmune disease
  • Subjects who have or have a history of allergic diseases (atopic dermatitis, bronchial asthma, etc.)
  • Subjects who have a history of hypersensitivity to any component of the investigational product
  • Subjects who are judged by the investigator (subinvestigator) to be ineligible for this clinical trial

结局指标

主要结局

-

Safety, tolerability and immunogenicity

次要结局

未报告次要终点

研究者

相似试验